key: cord-1005144-ptzfh4lq
authors: Yang, Haiyan; Hou, Hongjie; Liang, Xuan; Xu, Jie; Wang, Yadong
title: Lack of significant association between dyslipidemia and COVID-19 mortality
date: 2021-03-05
journal: J Infect
DOI: 10.1016/j.jinf.2021.03.001
sha: d216e3483b2072d597b582290bb4b45ccfce19a0
doc_id: 1005144
cord_uid: ptzfh4lq

nan

To the Editor, Recently, Aung et al reported that distribution frequency of angiotensin converting enzyme (ACE) insertion/insertion (II) genotype had a significant impact on coronavirus disease 2019 (COVID-19) mortality (1) . Dyslipidemia is one of the most comorbidities among COVID-19 patients, however, the conclusions from published articles on the relationship between dyslipidemia and COVID-19 mortality are still controversial. For instance, several studies found that there was a significant relationship between dyslipidemia and an increased risk for mortality among COVID-19 patients (2) (3) (4) , while other studies reported dyslipidemia was not significantly associated with COVID-19 mortality (5, 6) . Therefore, there is an urgent need to address the relationship between dyslipidemia and COVID-19 mortality by a quantitative meta-analysis. It has been reported that demographical characteristics (age and gender) and certain comorbidities (diabetes mellitus, cardiovascular disease, hypertension, chronic kidney disease and autoimmune diseases, etc.) are well-known modulators that affect the clinical outcomes of COVID-19 patients (7-9), suggesting that these factors might modulate the relationship between dyslipidemia and COVID-19 mortality. Thus, in this current meta-analysis, risk factors-adjusted effect estimates rather than crude effect estimates were utilized to calculate the pooled effect sizes.

We did this systematic meta-analysis in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). All potentially eligible articles published between January 1, February 26, 2021 were identify in the online databases (PubMed, Web of Science and EMBASE) with the following keywords: "SARS-CoV-2" or "severe acute respiratory syndrome coronavirus 2" or "COVID-19" or "coronavirus disease 2019" or "2019-nCoV" and "dyslipidemia" or "hyperlipidemia" or "low-density lipoprotein" or "high-density lipoprotein" or "triglycerides" or "total cholesterol". Reference lists of eligible articles were also searched to look for additional studies. The exposure group was defined as COVID-19 patients with dyslipidemia and the control group was defined as COVID-19 patients without dyslipidemia. The outcome of interest was mortality, which was defined as mortality, death, died, non-survivor, fatality or deceased. All peer-reviewed articles published in English language reporting the risk factors-adjusted effect estimate on the relationship between dyslipidemia and COVID-19 mortality were eligibly selected. Accordingly, we excluded preprints, case reports, review papers, corrections, comments, animal studies and in vitro studies, studies reporting crude effect estimate, studies without sufficient data and studies reporting clinical outcomes as severe/critical illness, intensive care unit admission, mechanical ventilation/intubation or composite outcomes rather than mortality.

Essential information including first author, number of COVID-19 patients, gender distribution, age (mean and standard deviation (SD) or median and interquartile range (IQR)), study design, region/country, clinical outcomes, adjusted effect estimates and adjusted variables was extracted from each included study.

We utilized Stata (version 12.1) for all statistical analyses. The pooled effect estimate and its 95% confidence interval (CI) were computed using a random-effects model. Inter-study heterogeneity was investigated using the cochrane Q test and I 2 statistic, P < 0.1 or I 2 > 50% shows a statistically significant heterogeneity. The statistical stability of the overall effects was assessed using leave-one-out sensitivity analysis. The risk of publication bias was evaluated using Begg's test. Subgroup analyses were carried out by sample size, age, male percentage, study design and effect estimate. Two-tailed P-value < 0.05 was considered statistically significant.

Initial search yielded 2,608 articles. After screening eligible articles according to inclusion and exclusion criteria, a total of twenty-seven studies composing of 146,364 cases were enrolled into this quantitative meta-analysis. Among the included studies, twenty-four studies were retrospective, one was prospective, one was longitudinal cohort study and one was nationwide cohort study. The sample size across the eligible studies ranged from 98 to 35,302. There were sixteen odds ratio (OR)-reported studies, nine hazard ratio (HR)-reported studies, one risk ratio (RR)-reported study and one relative hazard (RH)-reported study.

The results of our pooled analysis are presented in Figure 1A , which indicates that there was no significant relationship between dyslipidemia and COVID-19 morality (pooled effect = 1.05 [0.99-1.12], P = 0.100; I 2 = 52.6%, random-effects model).

Sensitivity analysis by deleting each study one by one demonstrated that our results were stable ( Figure 1B) This meta-analysis has several limitations that need to be mentioned: (1) most of the included studies were from USA, which limits its wider applicability of the present findings; (2) the majority of studies were retrospective, thus further well-designed studies with more prospective researches are required to verify our results; (3) although the pooled effect estimate was calculated on the basis of adjusted effects, the adjusted variables are not completely consistent across the included studies; (4) only one included study explicitly states the specific type of dyslipidemia as total cholesterol (TC), additional studies does not explicitly states the specific type of dyslipidemia such as abnormal levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG) and TC. Further studies should focus on the relationship between specific type of dyslipidemia and COVID-19 mortality when more data are available; (5) the detailed information on medications for patients with pre-existing dyslipidemia is not available presently, thus we could not address the effects of medications on the relationship between dyslipidemia and COVID-19 mortality.

In conclusion, our current study based on adjusted effect sizes demonstrated that dyslipidemia was not significantly associated with COVID-19 mortality. Further well-designed studies with large sample sizes are warranted to confirm our findings. 

Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA internal medicine

Clinical Characterization of Patients With COVID-19 in Primary Care in Catalonia: Retrospective Observational Study. JMIR public health and surveillance

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Machine learning prediction for mortality of patients diagnosed with COVID-19: a nationwide Korean cohort study. Scientific reports

Conflicts of interest statement: The authors declare that they have no any potential conflict of interest regarding this submitted manuscript.